Investors were pleasantly surprised by an unexpected turnaround in aducanumab's clinical trial data, but how justified is the market's optimism?
What should investors think of this piece of news?
What should investors think of this biotech stock and its signature drug candidate Andexxa?
New breast cancer trial results could prove to be a major catalyst for the stock.
The company has given back most of its 2019 gains, but does this change its previously bullish appraisal?
Amid concerns about its $63 billion Allergan buyout, is now a good time to invest in the pharmaceutical giant?
Does this mean anything for the pharmaceutical giant's long-term outlook?
This energy giant is a staple in many portfolios, but what does the future hold?
The battered cannabis giant could become the dominant player in the athletics market.
The gene-editing sector has a bright future ahead, but does that make every company in that market a buy?
Despite working together on a major project, these two biotech stocks couldn't be more different from a growth perspective.
The company's flagship cholesterol treatment shows major potential.
More legal battles are on the horizon for Vale as other challenges emerge.
This cannabis stock is poised to see a significant fall sometime in the future.
A key gold mine in Mexico will be shut down due to protests.
Is the debt-laden British pharmaceutical giant a good investment now?
This small-cap cannabis producer might be one of the best investments in the sector.
With its head start in the emerging gene-editing market, does CRISPR deserve investors' money more than its rivals do?
What does the future hold for this marijuana giant now that its share price has fallen in recent weeks?
These two palladium producers are witnessing impressive growth right now.